Welcome to our dedicated page for DAXOR news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on DAXOR stock.
Daxor Corporation (NASDAQ: DXR) is a medical instrumentation and biotechnology company focused on blood volume measurement, and its news flow centers on developments in this specialized diagnostic area. The company describes itself as the global leader in blood volume measurement technology, with approximately 50 years of experience and a patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic platform.
News about Daxor frequently highlights regulatory milestones, such as FDA 510(k) clearance for its next-generation rapid, compact, hand-held, lab-based Blood Volume Analyzer (Daxor BVA™). Announcements also cover commercial expansion, including adoption of its BVA platform and ezBVA Lab Service by health systems, academic medical centers and cardiology practices, as well as deployments of on-site analyzers for immediate blood volume assessment.
Investors and clinicians following DXR can expect updates on clinical research that evaluates BVA-guided care in conditions like heart failure, LVAD implantation, cardiac amyloidosis, sepsis and COVID-19. Company releases summarize peer-reviewed studies and pilot trials that examine outcomes such as readmissions, survival, kidney injury and hospital length of stay when blood volume analysis is incorporated into care pathways.
Daxor’s news flow also includes participation in medical and investor conferences, where management presents corporate updates and showcases its technology to cardiovascular and critical care audiences, as well as institutional investors. For those tracking DXR, this news page offers a focused view of how the company’s blood volume analysis technology is progressing through regulatory clearance, clinical validation and market adoption over time.
Summary not available.
Daxor Corporation (NYSE: DXR) has received a grant from the Center for Advancing Point of Care Technologies to develop a smart heart failure diagnostic for intravascular fluid overload. This funding accelerates Daxor's R&D of next-generation devices for blood volume measurement, a critical need as heart failure affects over 6 million Americans annually. The point-of-care diagnostics market is projected to reach $46.7 billion by 2024, driven by a rising incidence of heart conditions and a shift towards home healthcare.
Daxor Corporation (NYSE: DXR) recently presented compelling findings at the Society for Critical Care Medicine's 50th Congress. A study conducted by the University of Hawaii revealed that the BVA-100 blood test effectively measures blood volume status post massive blood transfusions, outperforming traditional clinical metrics in 80% of cases analyzed. Only 20% of patients were found to be euvolemic, while 24% were hypovolemic despite normal clinical indicators. Daxor's BVA-100 test aims to enhance treatment precision, potentially improving patient outcomes in critical care settings.
Daxor Corporation (NYSE: DXR) announced its participation in the SCCM 50th Congress Virtual Event from January 31 to February 12, 2021, showcasing its BVA-100 blood test research from the University of Hawaii. The study indicates that BVA-100 can enhance patient care by significantly reducing mortality rates by 66% and altering SICU interventions in 44% of cases compared to standard methods. The company aims to improve healthcare outcomes through precise fluid management.
Daxor Corporation (NYSE: DXR) has entered into a distribution agreement with L1 Enterprises to promote its BVA-100 blood volume analysis test. This agreement targets federal healthcare agencies, including the Department of Defense and Veterans Affairs, to enhance patient care for conditions like heart failure and critical care.
CEO Michael Feldschuh emphasized the collaboration's potential to improve health outcomes for veterans, while L1 Enterprises highlighted the technology's role in reducing mortality rates and saving costs for the government.
Daxor Corporation (NYSE: DXR) announced that CEO Michael Feldschuh will present at the H.C. Wainwright BioConnect Investment Conference from January 11-14, 2021. He will discuss Daxor's innovative BVA-100® blood test, which has been used in over 50,000 assessments for various medical conditions, including heart failure. The company is also conducting a multi-center trial on COVID-19 and has contracts with the U.S. Department of Defense for advanced Blood Volume Analyzers.
Daxor Corporation (NYSE: DXR) has announced new acquisitions of its BVA-100® Blood Volume Analyzer by major medical centers, enhancing its presence in heart failure treatment. A leading Northeast academic center has integrated the device into inpatient protocols, while a Midwest clinic is utilizing it for outpatients. Additionally, three hospitals have renewed support agreements, reflecting the technology's value. The BVA-100® offers a cost-effective solution for fluid management, showing 80% lower costs compared to traditional therapies, and an average life-extension of 2.32 quality-adjusted life years.
Daxor Corporation (NYSE: DXR) announces that CEO Michael Feldschuh will present at the virtual 2020 LD MicroCap Main Event on December 14, 2020, at 10:40 AM ET. He will discuss the company's recent research on the BVA-100® blood test, focusing on its cost-effectiveness and benefits for heart failure patients. This event features a new format where presentations are followed by Q&A sessions. Interested investors can contact Bret Shapiro at COREIR for more information.
Daxor Corporation (NYSE: DXR) announced a collaboration with Wake Forest Baptist Health for an ongoing trial to treat COVID-19 patients using its BVA-100 technology. The participation of Wake Forest School of Medicine underscores the significance of Daxor's blood volume measurement in understanding COVID-related volume derangements. Daxor's BVA test is the first FDA-cleared diagnostic for assessing blood volume status and capillary leak rates, which are associated with higher mortality. Prior clinical trials revealed a 66% reduction in ICU mortality when utilizing BVA testing.
Daxor Corporation (NYSE: DXR) announces Oregon Health & Science University (OHSU) as a second site for a COVID-19 clinical trial using its Blood Volume Analyzer (BVA) technology. This partnership follows the earlier collaboration with NYU Langone Health. The BVA-100 is FDA-cleared and quantifies blood components, aiding in patient treatment strategies. The trial aims to investigate the implications of COVID-19 as an endothelial disease, with findings from previous studies indicating significant reductions in ICU mortality. The study is led by Dr. Martin A. Schreiber at OHSU.